drug · small molecule
brexpiprazole LAI
Phase 1updated 3mo agoby Bostal Drug Delivery Co Ltd🔗 ChEMBL
Phase 1community read0 votes
🐶 often sniffed alongside
top 5Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 9 investigational indications.
targets
5-hydroxytryptamine receptor 2A5-hydroxytryptamine receptor 1AD(2) dopamine receptor
all catalysts(0)
nothing on the calendar yet
Trials studying brexpiprazole LAI
- phase1Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia
- phase1Food Effect Study of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia
- phase3Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia
- phase1Bioequivalence Study to Compare Brexpiprazole 4 mg Film Coated Tablets Versus RXULTI 4 mg Film Coated Tablet (Brexpiprazole)
- phase1The Purpose of This Study is to Determine the Safety, Tolerability, and Pharmacokinetics of Brexpiprazole Long-acting Injection Following a Single Administration in Healthy Subjects/Patients With Schizophrenia.
- phase3Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder
- —Real-life Assessment of Brexpiprazole (Rexulti) in Schizophrenia and in Depressive Disorders
- —REXULTI Drug General Use-results Survey (Excessive Motor Activity or Physically/Verbally Aggressive Behavior Due to Rapid Changes in Mood, Irritability, and/or Outbursts Associated With Dementia Due to Alzheimer's Disease)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 52m ago
Found something off?
comments(0)
5-min edit window · permanent after that